# Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

> **NCT06598631** · PHASE2 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Volenrelaxin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06598631
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-09
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group.
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598631, "Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06598631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*